The MYG1 Knockout SK-HEP-1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human hepatocellular carcinoma cell line SK-HEP-1, engineered to disrupt the MYG1 gene. This loss-of-function model enables investigation of MYG1??s role in mitochondrial RNA processing and translation within hepatic epithelial cells.
SK-HEP-1 is a well-characterized human hepatocellular carcinoma cell line originally isolated from the ascites of a patient with liver adenocarcinoma. It exhibits epithelial morphology and retains hepatic features, making it a suitable model for studying hepatocarcinogenesis, metabolic reprogramming, and mitochondrial biology in liver cancer.
MYG1 encodes a mitochondrial protein containing a UPF0047 domain and is implicated in mitochondrial gene expression, likely participating in RNA processing or translation. It is transcriptionally regulated by key factors such as NRF1, TFAM, and PGC-1??, which coordinate mitochondrial biogenesis. MYG1 interacts with mitochondrial ribosomal proteins (MRPL and MRPS family members) and components of mitochondrial RNA granules, suggesting its involvement in the assembly or function of the mitochondrial ribosome. Disruption of MYG1 is therefore expected to impair mitochondrial translation, leading to reduced synthesis of respiratory chain subunits and consequently diminished oxidative phosphorylation and cellular ATP levels.
Given the reliance of hepatocellular carcinoma cells on mitochondrial metabolism for biosynthesis and energy production, MYG1 disruption in the SK-HEP-1 background offers a physiologically relevant system to study the impact of mitochondrial dysfunction on liver cancer cell proliferation and survival, particularly under metabolic stress conditions. This model may reveal context-specific dependencies on mitochondrial translation that are not apparent in normal hepatocytes, potentially uncovering synthetic lethal interactions or metabolic vulnerabilities unique to HCC.
Researchers can utilize the MYG1 Knockout SK-HEP-1 Polyclonal Cells to dissect mitochondrial contributions to hepatocellular carcinoma progression through a variety of functional assays, including Western blotting for oxidative phosphorylation (OXPHOS) subunits, RT-qPCR profiling of mitochondrial transcripts, and Seahorse respirometry to measure oxygen consumption and glycolytic rates. Metabolomic analysis via LC-MS can profile alterations in central carbon metabolism, while proliferation assays (MTT, Incucyte) and drug sensitivity screens enable identification of compounds that selectively target MYG1-deficient cells. Immunofluorescence staining can further assess changes in mitochondrial morphology. For additional details or customized cell solutions, please contact Ascent Research.
